Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tucatinib - Array BioPharma/Seagen

Drug Profile

Tucatinib - Array BioPharma/Seagen

Alternative Names: ARRY 380; Irbinitinib; MK 7119; ONT 380; TUKYSA

Latest Information Update: 28 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Merck & Co; Merck Sharp & Dohme; Novartis; Seagen
  • Class 2 ring heterocyclic compounds; Antineoplastics; Diamines; Oxazoles; Pyridines; Quinazolines; Small molecules; Triazoles
  • Mechanism of Action ERBB 2 receptor antagonists; Phosphorylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colorectal cancer; Breast cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Colorectal cancer
  • Phase II/III Gastrointestinal cancer
  • Phase II Biliary cancer; Bladder cancer; Cervical cancer; Endometrial cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Cholangiocarcinoma; Gallbladder cancer; Gastric cancer

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease) in USA (PO)
  • 11 Aug 2022 Seagen completes a phase II HER2CLIMB trial in Breast cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA, Canada, Australia, France, Austria, Belgium, Czech Republic, Denmark, Germany, Israel, Italy, Portugal, Spain, Switzerland and United Kingdom (PO) (NCT02614794)
  • 28 Jul 2022 Seagen submits a supplemental New Drug Application (sNDA) to the US FDA for the treatment Colorectal cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top